Abstract
Objectives
Ferroptosis is a unique process of cell death that specifically requires iron. We investigated ferroptosis genes and their function in lung adenocarcinoma (LUAD) patients.
Methods
Data on the expression levels of genes associated with ferroptosis were collected from the FerrDb and the Cancer Genome Atlas database. Kaplan-Meier Plotter was employed to generate the survival curves of LUAD patients with high vs low expression of ferroptosis genes. The relationship between immune cell infiltration and ferroptosis genes was analyzed via TIMMER. Immunohistochemical staining was employed to quantitatively evaluate gene expression in 43 LUAD patients.
Results
A total of 89 ferroptosis genes were found to have significant differential expression between LUAD and normal tissues (p<0.05), 23 of which were selected and consistent prognostic trends were observed based on analysis of RNA-Seq and RNA microarray data (p<0.05). These 23 ferroptosis genes were assigned to 10 high-abundance pathways and 18 functional categories. Besides, the expression of ALOX5 and FTL3 demonstrated a positive correlation with sets of immune markers. The expression of ALOX5 exhibited a positive correlation with the levels of infiltration of dendritic cells, macrophages, neutrophils, and CD4+ T cells, while FLT3 expression correlated with the infiltration of B cells, CD4+ T cells, neutrophils, and dendritic cells. Furthermore, ALOX5 was confirmed to be downregulated in lung tumor tissues (p<0.01).
Conclusions
Our findings show that the ferroptosis genes FLT3 and ALOX5 play prominent roles in immune cell infiltration during LUAD progression and may serve as prognostic biomarkers for LUAD.
Introduction
Primary lung cancer (LC) is a life-threatening malignancy with one of the highest morbidity and mortality rates globally, and lung adenocarcinoma (LUAD) is the most prevalent subtype of LC, comprising over 40% of all cases [1]. The prognosis for LUAD is typically unfavorable, as many developed countries report a 5-year relative survival rate of less than 20%, even with advanced detection and treatment [2]. Currently, chemotherapy is an important applied strategy in LC therapy, but LC still carries a high risk of death due to metastasis [3]. It is worth mentioning that the invasion and migration of LC cells, accompanied by their uncontrolled proliferation, which lead to their resistance to chemotherapy, result from aberrations in multiple molecular pathways and mechanisms [4]. Therefore, it is important to find effective drugs to treat LC.
The classical apoptotic mechanism is often used in targeted cancer therapy for the development of molecular anti-cancer drugs. However, emerging discoveries in non-apoptotic cell death such as pyroptosis have expanded our understanding of cancer resistance. Studies have indicated that pyroptosis can facilitate the targeted removal of certain cancerous cells or become activated in response to certain pathological condition [5]. Erastin, another small molecule that induces cancer, specifically targets RAS and triggers a distinct type of non-apoptotic cell death that relies on iron, known as “ferroptosis” [6, 7]. Ferroptosis is a unique type of cell death that differs from apoptosis and other forms of programmed cell death. This process depends on iron and is characterized by the accumulation of iron ions, lipid peroxidation, and an increase in lethal reactive oxygen species (ROS) [8]. Unlike other forms of cell death, ferroptosis is distinguished by its biochemical, morphological, and genetic features [9]. Morphologically, ferroptosis is marked by the presence of abnormally small mitochondria with an increased density of mitochondrial membranes, a reduction or disappearance of mitochondrial cristae, and fracturing of the outer mitochondrial membrane [10].
Dysregulation of ferroptosis is a common occurrence in various cancers and has been identified as a critical mechanism underlying treatment resistance. Consequently, targeting ferroptosis has emerged as a promising strategy for the treatment of cancer [11]. Ferroptosis is related to the prognosis of multiple cancer types, such as colon adenocarcinoma [12]. However, due to its complex process and few studies on ferroptosis in LC, although the inhibition of ferroptosis has been observed in LC cells, its related molecular mechanisms remain unclear [13]. Research has shown that cellular ferroptosis is intricately linked to both iron metabolism and ROS metabolism, with genes involved in these pathways being crucial regulators of ferroptosis [7]. Therefore, it holds significant clinical significance to search for important regulatory factors of ferroptosis, clarify the mechanism of inhibiting ferroptosis, and induce ferroptosis in LC therapy.
In our study, we obtained a list of ferroptosis genes from the FerrDb database. We retrieved and examined data from multiple databases to analyze the correlation between gene expression related to ferroptosis and overall survival (OS), as well as their interrelationships. We also performed correlation analysis between ferroptosis genes and constructed protein interaction networks. We conducted GO and KEGG functional classification enrichment to annotate the potential functions of the ferroptosis genes. Moreover, we examined the association between the expression of ferroptosis genes and markers of immune genes, and also explored the link between the expression of ferroptosis genes and six types of immune cells that infiltrate tissues. Our findings indicated that FLT3 and ALOX5 were identified as significant factors that could impact immune cell infiltration, making them potential prognostic biomarkers for LUAD.
Materials and methods
The Cancer Genome Atlas and FerrDb analysis
We retrieved transcriptome data from The Cancer Genome Atlas (TCGA) database, consisting of 522 patients with LUAD and 59 samples of normal lung tissue. FerrDb (http://www.zhounan.org/ferrdb) is an openly accessible database that provides information on the regulators, markers, and links to diseases related to ferroptosis. In this study, 108 drivers were selected for further study. The edgeR package from Bioconductor in R was employed to identify and analyze the differentially expressed genes (DEGs) between normal lung tissues and LUAD samples [14]. A significance threshold of p-value<0.05 was used for identifying differentially DEGs.
Kaplan–Meier survival plot
The Kaplan-Meier (K-M) Plotter (http://www.kmplot.com/analysis/) linked with PAN-CANCER software was employed to generate survival curves for LUAD patients based on their expression levels of ferroptosis genes [15]. The gene expression levels were categorized into two groups (high and low) using the median value, and subsequent survival analyses were conducted. Hazard ratio (HR) and logarithmic rank p values were calculated for 95% confidence intervals.
Gene correlation analysis
To further confirm the correlation between ferroptosis genes, we utilized the corrplot package in R to analyze the TCGA expression data and assess the expression level correlation coefficients using the Spearman method. On the x-axis of the analysis, the selected ferroptosis-related genes with significant differences in expression were represented, while on the y-axis, homologous genes were represented. Tumor and para-cancer tissues from LUAD patients were analyzed. To identify the functional classes of selected genes, STRING (https://string-db.org/) was utilized to create networks of protein-protein interactions (PPIs) via Cytoscape to reveal functional relationships between iron failure genes and the top 10 most relevant genes.
Functional analysis of selected ferroptosis genes
To examine the functions of the selected genes, pathway enrichment analysis was performed by submitting the selected genes to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, systematically analyzed the metabolic pathways and gene product functions in cells [16, 17]. Besides, gene ontology (GO) term enrichment analysis was perform by GOrilla online software [18]. The annotation, visualization, and synthetic discovery databases (DAVID) (https://david.ncifcrf.gov/) were also employed to conduct GO and KEGG pathway enrichment analysis. In line with the DAVID manual, 23 ferroptosis genes were uploaded, and their functions were subsequently mapped. The important molecular functions and pathways of the target genes were extracted. We used histograms and Bubble Diagram Drawing Software to represent the GO and KEGG results of the ferroptosis genes.
TIMER database analysis
To investigate the relationship between the expression level of 23 ferroptosis genes and the tumor immune-microenvironment in LUAD, the tumor immune estimation resource database (TIMER, https://cistrome.shinyapps.io/timer/) was applied to estimate the abundance of different types of immune cells that infiltrate tumors based on TCGA data via deconvolution statistics [19]. In addition, the “Correlation” module was utilized to explore the relationship between ferroptosis-related genes expression and a specific set of immune markers.
Patient selection and evaluation
The patients included in this study had primary LC treated at the Zhejiang Cancer Hospital (Zhejiang, China) from January 2014 to June 2021. The diagnosis of LC was established based on clinical and X-ray examinations and confirmed through histological analysis of tumor biopsies. The staging and TNM classification of the LC cases were determined according to the 8th edition of the American Joint Committee on Cancer (AJCC) guidelines. The inclusion criteria included previous surgery and histological confirmation of LUAD. Participants who had multiple organ dysfunction or a history of organ transplantation, lung squamous cell carcinoma (LUSC), or small cell lung cancer (SCLC) were excluded from the study, as well as those who were unwilling to participate. All participants in the study provided samples of their tumor tissues that had been embedded in paraffin, as well as paired paracancerous specimens, which were obtained during surgical operations. In addition to the tissue specimens, information about the participants’ clinical characteristics was collected in a careful manner.
IHC and H&E staining
Briefly, the paraffin-embedded tumor tissue specimens and paired paracancerous specimens were sectioned into 4-μm sections and subjected to hematoxylin and eosin (H&E) staining using the standard protocol. Additionally, the ALOX5 gene expression level of these samples was quantified by immunohistochemistry (IHC). IHC assays were performed using an automated analytical instrument (BenchMark ULTRA system, Roche, Basel, Switzerland) and stained with 5-LO Polyclonal Antibody (YT0027, Immunoway, Texas, USA) according to the manufacturers’ protocols. Microscopic examination of the tumor cells and IHC analysis was carried out using an optical microscope (BX43, Olympus, Tokyo, Japan). Two experienced pathologists independently assessed and scored the percentage of tumor cells and IHC results retrospectively.
Statistical analysis
Multivariate Cox regression and K-M analysis were conducted using IBM SPSS Statistics 20.0 (IBM, New York, USA). Additional statistical analysis was carried out using R software (version 3.5.2). The correlation between gene expression was evaluated using Spearman correlation, with the strength of correlation judged based on the following absolute values: 0.00–0.19, “very weak”; 0.20–0.39, “weak”; 0.40–0.59, “moderate”; 0.60–0.79, “strong”; 0.80–1.0, “very strong”. Inter-group differences in IHC quantitative results were analyzed using paired samples t-tests, with statistical significance determined by p<0.05. This same significance level was used as the inclusion standard in the analysis.
Results
Expression levels of ferroptosis genes in LUAD
We obtained 108 driver ferroptosis genes through the FerrDb database. The mRNA expression levels of iron ferroptosis genes were analyzed in TCGA using the edgeR package from Bioconductor in order to uncover disparities in their expression between LUAD and normal tissues. Building upon the results, 89 ferroptosis genes exhibited differential expression (p<0.05) between LUAD and normal tissues (Figure 1). Of these, 56 ferroptosis genes were up-regulated, among which 5 genes (MIOX, CDKN2A, TFR2, NOX5 and ALOXE3) had a log2 fold change (FC) greater than 2. Thirty-three ferroptosis genes were down-regulated, among which 3 genes (DUOX1, CDO1 and EPAS1) had a log2 FC less than −2 (Table S1).

Human ferroptosis gene expression levels in lung adenocarcinoma (LUAD) from TCGA. (A) Up-regulated genes. (B) Down-regulated genes. In the heatmap, the annotation “t” represents “tumor” and “n” represents “normal”, *p<0.05, **p <0.01, ***p<0.001.
Prognostic significance of ferroptosis genes in LUAD
We investigated and explored the potential association between ferroptosis gene expression and OS in LUAD. First, the effect of ferroptosis gene expression on survival rate was evaluated using TCGA. The findings indicated a significant correlation between the expression of ferroptosis genes and the prognosis of LUAD. Further evaluation of the impact of ferroptosis gene expression on the survival probability of LUAD patients was conducted using the K-M Plotter. Twenty-three ferroptosis genes were selected according to a P<0.05 and consistent prognostic trends based on data analysis from RNA-Seq and gene chips. The results of the data analysis based on RNA-Seq (Figure 2A) and RNA microarray (Figure 2B) showed that high expression of ferroptosis genes (CS, NOX5, G6PD, PGD, VDAC2, GOT1, HMOX1, ULK1, CDKN2A and HILPDA) was notably correlated with poor prognosis. On the contrary, patients with LUAD who had high expression levels of various other ferroptosis genes (FLT3, ALOX5, NCOA4, GABARAPL2, WIPL1, ZEB1, PEBP1, CDO1, EPAS1, TAZ, GLS2, ALOX15B, and DPP4) was markedly longer (Figure 2A, B).

Forest plot of the prognostic survival analysis of 23 ferroptosis genes. (A) Forest plot of the prognostic survival analysis of 23 ferroptosis genes based on RNA-Seq data analysis. (B) Forest plot of the prognostic survival analysis of 23 ferroptosis genes based on gene chip data.
Correlation analysis between ferroptosis genes and constructing protein interaction networks
We use the corrplot package in R to further verify the correlation between ferroptosis genes (Figure 3A) and observed that ALOX5 had a notable positive correlation with CDO1 (0.42) and EPSA1 (0.43). CS was positively correlated with VDAC2 (0.41). ZEB1 was positively correlated with EPAS1 (0.49), CDO1 (0.41) and FLT3 (0.44). Additionally, we observed a relatively stronger positive correlation between G6PD and PGD (0.64), as well as between CDO1 and EPAS1 (0.63). Finally, TAZ was negatively correlated with NCOA4 (−0.47).

Correlation analysis between ferroptosis genes and their interacting proteins in LUAD, and functional analysis of 23 ferroptosis genes. (A) Correlation analysis between the ferroptosis genes. The darker the color, the higher the correlation coefficient. Red and blue represent positive and negative correlation, respectively. (B) PPI network of ferroptosis genes including the top 10 proteins. (C) GO biological process analysis of 23 ferroptosis genes in LUAD. (D) KEGG pathway analysis of 23 ferroptosis genes in LUAD. The circle’s size and color show the number and −log10 (p-value), respectively. The x-axis represents the average score of genes in the specific KEGG terms. KEGG, Kyoto Encyclopedia of genes and genomes.
Functional interactions between proteins are essential for molecular mechanisms and the metabolism of malignant tumors. To confirm the interaction of ferroptosis proteins in LUAD progression, the STRING tool was utilized for the analysis of the PPI network. The top 10 proteins, along with their corresponding gene names and annotations, were listed in Table 1. The high degree of connectivity between these protein-protein pairs suggests that these ferroptosis proteins play critical roles during LUAD progression (Figure 3B).
Annotation of ferroptosis gene-interacting proteins.
Gene | Annotations |
---|---|
AR | Androgen receptor |
ATG101 | Autophagy-related protein 101 |
ATG13 | Autophagy-related protein 13 |
ATG7 | Ubiquitin-like modifier-activating enzyme |
ATG3 | Ubiquitin-like-conjugating enzyme |
CDH1 | Zinc finger E-box-binding homeobox 1 |
CDK4 | Cyclin-dependent kinase 4 |
RB1CC1 | RB1-inducible coiled-coil protein 1 |
PGLS | 6-phosphogluconolactonase |
H6PD | GDH/6PGL endoplasmic bifunctional protein |
Functional annotation of ferroptosis genes
By GO analysis, ferroptosis genes were grouped into biological processes, cell components, and molecular functions. The biological processes included pentose-phosphate shunting and pentose biosynthetic process. The cellular components primarily involved were pre-autophagosomal structure membrane and the molecular function analysis indicated a major involvement of oxidoreductase activity (Figure 3C).
By KEGG pathway analysis, the ferroptosis genes were mapped to 10 high-abundance KEGG pathways, among which four major pathways were cancer central carbon metabolism, cancer microRNAs, carbon metabolism, and antibiotic biosynthesis (Figure 3D). In addition, Tables S2 and S3 list the details of 23 ferroptosis genes in the three GO classes and pathways.
Correlation of ferroptosis gene expression with immune marker sets and immune infiltration levels
We further examine the correlation between the expression of ferroptosis genes and immune marker sets in LUAD. FLT3 expression was positively correlated with the expression of CD3E, CCR7, CD2, CD19, CD3D, CD79a, CD86 and CSF1R. ALOX5 was positively correlated with the expression of CD86, CSF1R, CD68, ITGAM, VISIG4, IRF5, CD163, MS4A4A, HLA-DPB1, HLA-DPA1, ITGAX and STAT5A (Figure 4A). These findings indicate that elevated levels of FLT3 and ALOX5 expression may have a significant impact on immune evasion. Moreover, our results suggests that high expressed FLT3 and ALOX5 is broadly linked to immunity in patients with LUAD. Besides, The relationship between the expression of FLT3 and ALOX5 and the infiltration levels of six main types of immune cells, which contains B cells, CD4+/ CD8+ T cells, dendritic cells (DCs), macrophages, and neutrophils was analyzed. The results displayed that FLT3 expression was positively associated with infiltration levels of B cells and moderately correlated with infiltration levels of CD4+ T cells, neutrophils, and DCs in LUAD (Figure 4B). Besides, ALOX5 expression demonstrated a positive correlation with infiltration levels of macrophages, neutrophils and CD4+ T cells, with the strongest correlation with the infiltration level of DCs in LUAD (Figure 4C).

Correlation of ferroptosis gene expression with immune marker sets and immune infiltration levels and IHC results. (A) Heat maps show the correlations between ferroptosis genes and immune marker sets correlations. The darker the color, the higher the correlation coefficient. Red and blue represent positive and negative correlation, respectively. (B) FLT3 was positively correlated with infiltrating levels of B cells and was moderately correlated with infiltration levels of CD4+ T cells, neutrophils and DCs in LUAD. (C) ALOX5 expression was positively correlated with the infiltration level of macrophages, neutrophils and CD4+ T cells, with the strongest correlation with the infiltration level of DCs in LUAD. p<0.05 was considered statistically significant. (D) Box-plot of IHC results in tumor tissue and matched paracancerous tissue, p<0.01. (E) H&E and IHC staining results.
Patient characteristics
From 2020 to 2021, we recruited 43 newly diagnosed LC patients to investigate any potential differences in ALOX5 expression between tumor tissue and paracancerous tissue. The study participants had a median age of 61 years, and their tumor size and TNM stage were carefully assessed and recorded (Table S4). Table 2 provides a summary of their characteristics. For each patient, we obtained paraffin-embedded tumor tissue specimens and paired paracancerous specimens through surgical procedures, which were then subjected to H&E and IHC staining.
Patient characteristics.
Characteristics | All patients |
---|---|
43 | |
Gender | |
Male | 23 (53.5%) |
Female | 20 (46.5%) |
Age at diagnosis in years | |
<60 | 15 (34.9%) |
≥60 | 28 (65.1%) |
Habits | |
Smoking | 18 (41.9%) |
Alcohol | 8 (18.6%) |
Tumor size | |
≤3 cm | 37 (86.0%) |
>3 cm | 6 (14.0%) |
Tumor stage | |
0 | 2 (4.7%) |
I | 21 (48.8%) |
II | 1 (2.3%) |
III | 2 (4.7%) |
IV | 2 (4.7%) |
IHC assay of ALOX5 protein expression
IHC assay was performed on the 43 patient-derived samples to quantify the ALOX5 protein expression level. Based on the positive signal intensity, samples were divided into ++, +∼++, and + levels, corresponding to a score of 1, 2 and 3, respectively. Additionally, the samples were scored 0, 1, 2, 3 and 4, corresponding to the percentage of positive cells for ALOX5 as follows: 0%, ≤25%, 26%–50%, 51%–75% and >75%, respectively. The final score of the ALOX5 expression level is the multiplication of these two scores (Table S4). Our results showed that compared with normal tissue, ALOX5 expression significantly decreased in tumor tissue (p <0.01), indicating that it is a potential biomarker in LC diagnostic (Figure 4D, E).
4 Discussion
Ferroptosis is being widely acknowledged as a potential model for developing efficacious combination therapy approaches in the treatment of cancer [20, 21]. Because first-line treatment options for LUAD patients are constantly changing, and it is essential to take into account the tumor biology and microenvironment while anticipating the most effective therapeutic strategies [22]. In comparison to normal tissues, our findings revealed an up-regulation of 56 ferroptosis genes and a down-regulation of 33 iron ferroptosis genes (Table S1). A K-M curve plotter revealed that the expression of 23 ferroptosis genes had consistent prognostic trends based on the data analysis from RNA-Seq and RNA microarrays (Figure 2A, B), and these ferroptosis genes play critical roles during LUAD progression (Figure 3). FLT3 and ALOX5 expression can serve as novel factors for stratifying patients with LUAD, thereby assisting in the selection of appropriate treatment options such as ferroptosis or immunotherapy. Furthermore, they may also contribute to the prognostic evaluation of LUAD patients.
Belonging to the class III receptor tyrosine kinase family, FLT3 is similar to other receptors such as the macrophage colony-stimulating factor receptor, platelet-derived growth factor receptor, and stem cell factor receptor. Upon binding of its extracellular ligand, FLT3 gets activated and induces cell proliferation, differentiation, and survival via various signaling pathways, including Ras, PI3K, and STAT5 [23]. Several studies conducted on cancer models have revealed that activating mutations in FLT3 augment the levels of ROS, which can be inhibited by the suppression of FLT3, and FLT3 inhibitors were shown to block ferroptotic cell death in neurons [24, 25]. Intriguingly, FLT3 deficiency can prevent the production of ROS, mitochondrial hyperpolarization and lipid peroxidation in neuronal cells, which induces ferroptosis [26]. Herein, we investigated the role of FLT3 expression in the progression and prognosis of LUAD based on various databases. Absence of FLT3 is linked to the occurrence and progression of LUAD, and patients with LUAD who exhibit low expression of FLT3 have a poorer prognosis compared to those with high FLT3 expression.
ALOX5 is an enzyme that transforms arachidonic acid into 5-hydroperoxy-eicostetraenoic acid, which can be further converted into leukotriene A4 (LTA4) and 5-hydroxyicosatetraenoic acid (5-HETE). LTA4 is a bioactive lipid that is implicated in cancer and inflammation [27]. Research has shown that ALOX5 and its byproduct 5-HETE are upregulated in cancer cells, providing them with a growth advantage [28, 29], and contributing to the survival and proliferation of breast cancer cells [30]. However, the function of ALOX5 in LUAD remains unclear. This research is the first to reveal that ALOX5 expression is reduced in LUAD compared to the control group (Table S1). Variation in ALOX5 expression level was found to be associated with the prognosis of LUAD patients, with low expression indicating a worse prognosis (Figure 2A,B). In addition, our findings indicate a correlation between ALOX5 expression levels and the degree of immune infiltration, as well as various immune markers. Thus, this study sheds light on the potential involvement of ALOX5 in tumor immunology and its utility as a biomarker or therapeutic target in cancer treatment.
Another important aspect of this study was the positive correlation observed between FLT3 and ALOX5 expression levels and immune marker sets (Figure 4A). Furthermore, we examined how the expression of FLT3 and ALOX5 relates to various levels of immune infiltration in LUAD. Our results indicate that ALOX5 expression has a moderate correlation with macrophage, neutrophil, and CD4+ T cell infiltration, with the strongest correlation found with DC infiltration (Figure 4B,C). However, the expression of FLT3 was positively correlated with the infiltration levels of CD4+ T cells, neutrophils and DCs, and the strongest correlation was found with the infiltration levels of B cells in LUAD. These findings suggest that FLT3 and ALOX5 may significantly impact immune evasion through their effects on immune cell infiltration and could potentially serve as prognostic biomarkers for LUAD.
Despite the promising findings of this study, there are some limitations that need to be addressed. Firstly, further in vivo and in vitro experiments are needed to confirm and elucidate the molecular mechanisms that underlie the relationship between FLT3 and ALOX5 expression and immune response. Secondly, the small sample size and single-center design of this study may limit the generalizability of the findings. Thus, larger prospective studies conducted across multiple centers are needed to fully explore the diagnostic and prognostic potential of FLT3 and ALOX5 expression in LC patients.
Conclusions
In summary, our initial findings propose that FLT3 and ALOX5 ferroptosis genes could potentially have significant roles in both immune cell infiltration and progression of LUAD. These genes may also be considered as potential prognostic biomarkers for LUAD (Figure 5).

Summary diagram.
Funding source: Key Technology Innovation Projects of Jiaxing
Award Identifier / Grant number: 2021BZ10004
Funding source: Medical Health Science and Technology Project of Zhejiang Provincial
Award Identifier / Grant number: 2021RC042
Funding source: Natural Science Foundation of Zhejiang Province
Award Identifier / Grant number: LQ20H260003
Acknowledgments
This manuscript was edited by the International Science Editing (http://www.internationalscienceediting.com).
-
Research funding: This work was supported by the Natural Science Foundation of Zhejiang Province [grant number LQ20H260003], the Medical Health Science and Technology Project of Zhejiang Provincial [grant number 2021RC042], the Key Technology Innovation Projects of Jiaxing [grant number 2021BZ10004].
-
Author contributions: (I) Conception and design: Yuansi Zheng, Jieyi Li. (II) Administrative support: Yaunsi Zheng. (III) Provision of study materials or patients: Ying Su, Lei Ruan. (IV) Collection and assembly of data: Qingfeng He, Linna Gong. (V) Data analysis and interpretation: Yuansi Zheng, Jieyi Li. (VI) Manuscript writing: Yuansi Zheng, Jieyi Li. (VII) Final approval of manuscript: All authors.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from ethics board of Zhejiang Cancer Hospital and individual consent for this retrospective analysis was waived.
-
Ethical approval: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional ethics board of Zhejiang Cancer Hospital (NO. IRB-2020-302) and individual consent for this retrospective analysis was waived.
References
1. Siegel, RL, Miller, KD, Fuchs, HE, Jemal, A. Cancer statistics, 2021. CA Cancer J Clin 2021;71:71–33. https://doi.org/10.3322/caac.21654.Suche in Google Scholar PubMed
2. Thai, AA, Solomon, BJ, Sequist, LV, Gainor, JF, Heist, RS. Lung cancer. Lancet 2021;398:535–54. https://doi.org/10.1016/s0140-6736(21)00312-3.Suche in Google Scholar
3. Hirsch, FR, Scagliotti, GV, Mulshine, JL, Kwon, R, Curran, WJJr., Wu, YL, et al.. Lung cancer: current therapies and new targeted treatments. Lancet 2017;389:299–311. https://doi.org/10.1016/s0140-6736(16)30958-8.Suche in Google Scholar PubMed
4. Pastushenko, I, Mauri, F, Song, Y, de Cock, F, Meeusen, B, Swedlund, B, et al.. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature 2021;589:448–55. https://doi.org/10.1038/s41586-020-03046-1.Suche in Google Scholar PubMed PubMed Central
5. Xie, J, Li, H, Chen, L, Cao, Y, Hu, Y, Zhu, Z, et al.. A novel pyroptosis-related lncRNA signature for predicting the prognosis of skin cutaneous melanoma. Int J Gen Med 2021;14:6517–27. https://doi.org/10.2147/ijgm.s335396.Suche in Google Scholar PubMed PubMed Central
6. Stockwell, BR, Friedmann Angeli, JP, Bayir, H, Bush, AI, Conrad, M, Dixon, SJ, et al.. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017;171:273–85. https://doi.org/10.1016/j.cell.2017.09.021.Suche in Google Scholar PubMed PubMed Central
7. Xie, Y, Hou, W, Song, X, Yu, Y, Huang, J, Sun, X, et al.. Ferroptosis: process and function. Cell Death Differ 2016;23:369–79. https://doi.org/10.1038/cdd.2015.158.Suche in Google Scholar PubMed PubMed Central
8. Dixon, SJ, Stockwell, BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol 2014;10:9–17. https://doi.org/10.1038/nchembio.1416.Suche in Google Scholar PubMed
9. Ji, X, Qian, J, Rahman, SMJ, Siska, PJ, Zou, Y, Harris, BK, et al.. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene 2018;37:5007–19. https://doi.org/10.1038/s41388-018-0307-z.Suche in Google Scholar PubMed PubMed Central
10. Lai, Y, Zhang, Z, Li, J, Li, W, Huang, Z, Zhang, C, et al.. STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma. Biochem Biophys Res Commun 2019;519:659–66. https://doi.org/10.1016/j.bbrc.2019.09.032.Suche in Google Scholar PubMed
11. Bebber, CM, Müller, F, Prieto Clemente, L, Weber, J, von Karstedt, S. Ferroptosis in cancer cell biology. Cancers 2020;12:164. https://doi.org/10.3390/cancers12010164.Suche in Google Scholar PubMed PubMed Central
12. Qiu, Y, Li, H, Zhang, Q, Qiao, X, Wu, J. Ferroptosis-related long noncoding RNAs as prognostic marker for colon adenocarcinoma. Appl Bionics Biomech 2022;2022:5220368–19. https://doi.org/10.1155/2022/5220368.Suche in Google Scholar PubMed PubMed Central
13. Yang, WS, SriRamaratnam, R, Welsch, ME, Shimada, K, Skouta, R, Viswanathan, VS, et al.. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014;156:317–31. https://doi.org/10.1016/j.cell.2013.12.010.Suche in Google Scholar PubMed PubMed Central
14. Robinson, MD, McCarthy, DJ, Smyth, GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139–40. https://doi.org/10.1093/bioinformatics/btp616.Suche in Google Scholar PubMed PubMed Central
15. Győrffy, B, Surowiak, P, Budczies, J, Lánczky, A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 2013;8:e82241. https://doi.org/10.1371/journal.pone.0082241.Suche in Google Scholar PubMed PubMed Central
16. Stelzl, U, Worm, U, Lalowski, M, Haenig, C, Brembeck, FH, Goehler, H, et al.. A human protein-protein interaction network: a resource for annotating the proteome. Cell 2005;122:957–68. https://doi.org/10.1016/j.cell.2005.08.029.Suche in Google Scholar PubMed
17. Kanehisa, M, Furumichi, M, Sato, Y, Ishiguro-Watanabe, M, Tanabe, M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res 2021;49:D545–51. https://doi.org/10.1093/nar/gkaa970.Suche in Google Scholar PubMed PubMed Central
18. Eden, E, Navon, R, Steinfeld, I, Lipson, D, Yakhini, Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinf 2009;10:48. https://doi.org/10.1186/1471-2105-10-48.Suche in Google Scholar PubMed PubMed Central
19. Tang, Z, Li, C, Kang, B, Gao, G, Li, C, Zhang, Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017;45:W98–102. https://doi.org/10.1093/nar/gkx247.Suche in Google Scholar PubMed PubMed Central
20. Friedmann Angeli, JP, Krysko, DV, Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer 2019;19:405–14. https://doi.org/10.1038/s41568-019-0149-1.Suche in Google Scholar PubMed
21. Lang, X, Green, MD, Wang, W, Yu, J, Choi, JE, Jiang, L, et al.. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov 2019;9:1673–85. https://doi.org/10.1158/2159-8290.cd-19-0338.Suche in Google Scholar
22. Huang, T, Sun, Y, Li, Y, Wang, T, Fu, Y, Li, C, et al.. Growth inhibition of a novel iron chelator, DpdtC, against hepatoma carcinoma cell lines partly attributed to ferritinophagy-mediated lysosomal ROS generation. Oxid Med Cell Longev 2018;2018:4928703–13. https://doi.org/10.1155/2018/4928703.Suche in Google Scholar PubMed PubMed Central
23. Grafone, T, Palmisano, M, Nicci, C, Storti, S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Onco Rev 2012;6:e8. https://doi.org/10.4081/oncol.2012.e8.Suche in Google Scholar PubMed PubMed Central
24. Sallmyr, A, Fan, J, Datta, K, Kim, KT, Grosu, D, Shapiro, P, et al.. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 2008;111:3173–82. https://doi.org/10.1182/blood-2007-05-092510.Suche in Google Scholar PubMed
25. Woolley, JF, Naughton, R, Stanicka, J, Gough, DR, Bhatt, L, Dickinson, BC, et al.. H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling. PLoS One 2012;7:e34050. https://doi.org/10.1371/journal.pone.0034050.Suche in Google Scholar PubMed PubMed Central
26. Kang, Y, Tiziani, S, Park, G, Kaul, M, Paternostro, G. Cellular protection using Flt3 and PI3Kα inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity. Nat Commun 2014;5:3672. https://doi.org/10.1038/ncomms4672.Suche in Google Scholar PubMed PubMed Central
27. Wang, D, Dubois, RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181–93. https://doi.org/10.1038/nrc2809.Suche in Google Scholar PubMed PubMed Central
28. Kummer, NT, Nowicki, TS, Azzi, JP, Reyes, I, Iacob, C, Xie, S, et al.. Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction. J Cell Biochem 2012;113:1998–2008. https://doi.org/10.1002/jcb.24069.Suche in Google Scholar PubMed PubMed Central
29. Menna, C, Olivieri, F, Catalano, A, Procopio, A. Lipoxygenase inhibitors for cancer prevention: promises and risks. Curr Pharmaceut Des 2010;16:725–33. https://doi.org/10.2174/138161210790883822.Suche in Google Scholar PubMed
30. Kumar, R, Singh, AK, Kumar, M, Shekhar, S, Rai, N, Kaur, P, et al.. Serum 5-LOX: a progressive protein marker for breast cancer and new approach for therapeutic target. Carcinogenesis 2016;37:912–7. https://doi.org/10.1093/carcin/bgw075.Suche in Google Scholar PubMed
Supplementary Material
This article contains supplementary material (https://doi.org/10.1515/oncologie-2023-0090).
© 2023 the author(s), published by De Gruyter, Berlin/Boston
This work is licensed under the Creative Commons Attribution 4.0 International License.
Artikel in diesem Heft
- Frontmatter
- Research Articles
- Experience of patients with metastatic breast cancer in France: results of the 2021 RÉALITÉS survey and comparison with 2015 results
- An evaluation of cancer aging research group (CARG) score to predict chemotherapy toxicity in older Iranian patients with cancer
- Anemarrhenasaponin I suppresses ovarian cancer progression via inhibition of SHH signaling pathway
- Early diagnosis and prognosis of hepatocellular carcinoma based on a ceRNA array
- Treatment with camrelizumab plus tyrosine kinase inhibitors with or without TACE for intermediate-advanced hepatocellular carcinoma: a clinical efficacy and safety study
- CISD2 protects against Erastin induced hepatocellular carcinoma ferroptosis by upregulating FSP1
- Screening and biomarker assessment of ferroptosis genes FLT3 and ALOX5 in lung adenocarcinoma
- Anoikis-related gene signature as novel prognostic biomarker to predict immunotherapy with bladder urothelial carcinoma
- Effects of stress response induced by laparoscopic colectomy and laparotomy on TLR-mediated innate immune responses in colon cancer patients
- CSF-1R promotes vasculogenic mimicry via epithelial-mesenchymal transition in nasopharyngeal carcinoma cells
- Case Report
- Anaplastic extramedullary plasmacytoma resistant to novel therapies: a case report
- Miscellaneous
- A summary of the second MACR international scientific conference (2nd MSC)
Artikel in diesem Heft
- Frontmatter
- Research Articles
- Experience of patients with metastatic breast cancer in France: results of the 2021 RÉALITÉS survey and comparison with 2015 results
- An evaluation of cancer aging research group (CARG) score to predict chemotherapy toxicity in older Iranian patients with cancer
- Anemarrhenasaponin I suppresses ovarian cancer progression via inhibition of SHH signaling pathway
- Early diagnosis and prognosis of hepatocellular carcinoma based on a ceRNA array
- Treatment with camrelizumab plus tyrosine kinase inhibitors with or without TACE for intermediate-advanced hepatocellular carcinoma: a clinical efficacy and safety study
- CISD2 protects against Erastin induced hepatocellular carcinoma ferroptosis by upregulating FSP1
- Screening and biomarker assessment of ferroptosis genes FLT3 and ALOX5 in lung adenocarcinoma
- Anoikis-related gene signature as novel prognostic biomarker to predict immunotherapy with bladder urothelial carcinoma
- Effects of stress response induced by laparoscopic colectomy and laparotomy on TLR-mediated innate immune responses in colon cancer patients
- CSF-1R promotes vasculogenic mimicry via epithelial-mesenchymal transition in nasopharyngeal carcinoma cells
- Case Report
- Anaplastic extramedullary plasmacytoma resistant to novel therapies: a case report
- Miscellaneous
- A summary of the second MACR international scientific conference (2nd MSC)